Table 3.
Analysis of association of gout risk with lipid and apo B-associated traits in study sample sets
| NU vs. Gout | HU vs. Gout | |||||||
|---|---|---|---|---|---|---|---|---|
| Unadjusted OR [95% CI] | P | Adjusted OR [95% CI] | P | Unadjusted OR [95% CI] | P | Adjusted OR [95% CI] | P | |
| Total Tg (mmol/L) | ||||||||
| Europeans | 2.34 [1.22-4.49] | 0.011 | 1.37 [0.70-2.65] | 0.36 | 1.21 [0.73-1.99] | 0.46 | 1.31 [0.72-2.40] | 0.38 |
| Polynesians | 1.41 [1.00-1.98] | 0.049 | 1.00 [0.51-1.98] | 0.99 | 1.17 [0.85-1.62] | 0.34 | 1.14 [0.75-1.75] | 0.54 |
| Combined | 1.59 [1.17-2.17] | 0.003 | 1.19 [0.80-1.75] | 0.39 | 1.18 [0.90-1.54] | 0.24 | 1.20 [0.88-1.65] | 0.25 |
| Total FPLC Tg (mmol/L) | ||||||||
| Europeans | 4.17 [1.51-11.51] | 0.006 | 1.97 [0.75-5.15] | 0.17 | 4.37 [1.49-12.81] | 0.007 | 5.19 [1.39-19.33] | 0.014 |
| Polynesians | 1.29 [0.80-2.10] | 0.30 | 0.65 [0.28-1.50] | 0.31 | 1.51 [0.82-2.78] | 0.19 | 1.52 [0.68-3.41] | 0.31 |
| Combined | 1.74 [1.14-2.64] | 0.01 | 1.17 [0.69-1.96] | 0.56 | 2.05 [1.23-3.42] | 0.006 | 2.14 [1.17-3.90] | 0.014 |
| VLDL Tg (mmol/L) | ||||||||
| Europeans | 11.29 [2.40-53.00] | 0.002 | 3.24 [0.87-12.07] | 0.080 | 6.52 [1.70-24.99] | 0.006 | 7.61 [1.60-36.26] | 0.011 |
| Polynesians | 1.92 [1.01-3.67] | 0.048 | 0.98 [0.34-2.81] | 0.97 | 2.46 [1.11-5.44] | 0.026 | 2.84 [0.92-8.76] | 0.069 |
| Combined | 2.78 [1.55-4.99] | 0.001 | 1.81 [0.87-3.75] | 0.11 | 3.19 [1.62-6.24] | 0.001 | 3.56 [1.60-7.92] | 0.002 |
| Total apoB ( μmol/L) | ||||||||
| Europeans | 0.97 [0.36-2.63] | 0.95 | 0.83 [0.18-3.76] | 0.81 | 2.71 [0.94-7.76] | 0.064 | 3.32 [0.87-12.61] | 0.078 |
| Polynesians | 0.47 [0.18-1.23] | 0.12 | 0.27 [0.04-1.73] | 0.17 | 13.38 [1.48-120.76] | 0.021 | 33.55 [1.16-972.93] | 0.041 |
| Combined | 0.65 [0.34-1.26] | 0.20 | 0.78 [0.32-1.93] | 0.59 | 3.60 [1.41-9.17] | 0.007 | 5.60 [1.73-18.18] | 0.004 |
| VLDL apo B (0.1 μmol/L) | ||||||||
| Europeans | 17.80 [2.99-106.02] | 0.002 | 10.05 [1.16-87.35] | 0.036 | 1.69 [0.74-3.86] | 0.21 | 1.67 [0.62-4.51] | 0.31 |
| Polynesians | 2.24 [0.89-5.60] | 0.086 | 1.97 [0.48-8.12] | 0.35 | 1.51 [0.61-3.73] | 0.38 | 2.42 [0.70-8.36] | 0.16 |
| Combined | 4.23 [1.87-9.59] | 0.001 | 2.68 [1.03-6.95] | 0.043 | 1.60 [0.87-2.93] | 0.13 | 1.57 [0.80-3.09] | 0.19 |
| VLDL Tg:VLDL apo B | ||||||||
| Europeans | 1.06 [0.97-1.16] | 0.20 | 1.02 [0.90-1.16] | 0.78 | 1.06 [0.97-1.17] | 0.20 | 1.02 [0.91-1.15] | 0.68 |
| Polynesians | 1.05 [0.99-1.10] | 0.086 | 1.03 [0.99-1.07] | 0.19 | 1.08 [1.01-1.15] | 0.024 | 1.08 [0.99-1.18] | 0.061 |
| Combined | 1.04 [1.00-1.09] | 0.051 | 1.03 [0.99-1.06] | 0.15 | 1.06 [1.01-1.12] | 0.016 | 1.06 [1.00-1.12] | 0.045 |
Adjusted for age, BMI, type 2 diabetes, SSB intake (drinks/day), alcohol intake (drinks/week), eGFR, hypertension and prescription of lipid-lowering medication. The Polynesian data are also adjusted by number of self-reported Polynesian grandparents. The combined analysis was additionally adjusted by ancestral group. NU: normouricaemia; HU: hyperuricaemia; OR: odds ratio; CI: confidence interval; Tg: triglyceride; FPLC: fast protein liquid chromatography; VLDL: very low-density lipoprotein; apo B: apolipoprotein B; BMI, body mass index; SSB: sugar-sweetened beverage; eGRF: estimated glomerular filtration rate.